Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte raises £40m from new and existing investors

Thu, 04th Feb 2021 09:41

(Sharecast News) - Cell engineering and life sciences company MaxCyte has announced a subscription to raise £40m, in a bid to strengthen its balance sheet.
The AIM-traded firm said the fundraising consisted of subscriptions via a private placement of 5,740,000 new shares at a price of 700p each, representing a premium of about 4.5% to its mid-market closing price as at 2 February.

It said the subscription provided a strategic capitalisation round to introduce new crossover investors to its share register, as it progressed its pursuit of a dual listing on Nasdaq in 2021, which the board said remained on track.

Subscribers included a mix of new and existing investors, including D1 Capital Partners, funds and accounts advised by T. Rowe Price Associates, ArrowMark Partners, Baron Capital Group and First Light Asset Management, alongside existing investors Casdin Capital and Sofinnova Partners.

Proceeds from the subscription would be used to strengthen MaxCyte's balance sheet, to enable it to support the "burgeoning field" of next-generation cell therapeutic development via its best-in-class cell engineering approaches.

"I am delighted to welcome new life science specialist investors to MaxCyte, joining existing shareholders Sofinnova Partners and Casdin Capital in this successful transaction," said president and chief executive officer Doug Doerfler.

"The financing will strengthen the company's balance sheet as we continue to focus on accelerating revenue growth in 2021 and beyond, and marks a further important step towards our goal to dual-list on Nasdaq in 2021."

At 0924 GMT, shares in MaxCyte were up 14.93% at 770p.
More News
8 Mar 2023 15:54

UK earnings, trading statements calendar - next 7 days

Thursday 9 March 
Aviva PLCFull Year Results
ConvaTec Group PLCFull Year Results
Digital 9 Infrastructure PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
DS Smith PLCTrading Statement
Endeavour Mining PLCFull Year Results
Entain PLCFull Year Results
Forterra PLCFull Year Results
Franchise Brands PLCFull Year Results
Hammerson PLCFull Year Results
Harbour Energy PLCFull Year Results
Hansard Global PLCHalf Year Results
Headlam Group PLCFull Year Results
Informa PLCFull Year Results
Kier Group PLCHalf Year Results
M&G PLCFull Year Results
Network International Holdings PLCFull Year Results
Oakley Capital Investments LtdFull Year Results
PageGroup PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Spirax-Sarco Engineering PLCFull Year Results
Volution Group PLCHalf Year Results
Wheaton Precious Metals CorpFull Year Results
Friday 10 March 
Allianz Technology Trust PLCFull Year Results
Berkeley Group HoldingsTrading Statement
BP PLCFull Year Results
FBD Holdings PLCFull Year Results
Lancashire Holdings LtdFull Year Results
Mineral & Financial Investments LtdHalf Year Results
Robert Walters PLCFull Year Results
Monday 13 March 
Direct Line Insurance Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
HgCapital Trust PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Nightcap PLCHalf Year Results
Phoenix Group Holdings PLCFull Year Results
Stelrad Group PLCFull Year Results
Tuesday 14 March 
Aptamer Group PLCHalf Year Results
Close Brothers Group PLCHalf Year Results
Costain Group PLCFull Year Results
Eagle Eye Solutions Group PLCHalf Year Results
Genuit Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
H&T Group PLCFull Year Results
Harworth Group PLCFull Year Results
Litigation Capital Management LtdHalf Year Results
Midwich Group PLCFull Year Results
Old Mutual LtdFull Year Results
PCI-PAL PLCHalf Year Results
Pennon Group PLCTrading Statement
Sabre Insurance Group PLCFull Year Results
Smart Metering Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Virgin Wines UK PLCHalf Year Results
Yu Group PLCFull Year Results
Wednesday 15 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
FDM Group Holdings PLCFull Year Results
Ferrexpo PLCFull Year Results
Foresight Solar Fund LtdFull Year Results
IG Group Holdings PLCQ3 Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Marshalls PLCFull Year Results
MaxCyte IncFull Year Results
Prudential PLCFull Year Results
Trainline PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
7 Mar 2023 10:51

MaxCyte revenue grows in 2022, expects further revenue climb in 2023

(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023.

Read more
7 Mar 2023 09:32

MaxCyte flags 2022 revenue growth, sets new guidance

(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.

Read more
30 Jan 2023 16:23

TRADING UPDATES: DP Eurasia annual sales grow despite Russia decline

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Jan 2023 08:56

MaxCyte signs strategic platform licence with Catamaran Bio

(Alliance News) - MaxCyte Inc on Wednesday said it signed a strategic platform licence with biotechnology company Catamaran Bio Inc.

Read more
4 Jan 2023 07:45

MaxCyte signs strategic platform licence with Catamaran Bio

(Sharecast News) - Commercial cell engineering company MaxCyte announced the signing of a strategic platform licence (SPL) with Catamaran Bio on Wednesday.

Read more
5 Dec 2022 21:49

TRADING UPDATES: MaxCyte in deal; Angus to resume Saltfleetby drilling

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Dec 2022 13:28

MaxCyte inks deal with South Korea's Curamys

(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence with South Korea-based biotechnology specialist Curamys on Monday, which develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

Read more
10 Nov 2022 13:06

MaxCyte revenues improve in third quarter

(Sharecast News) - Cell engineering technology specialist MaxCyte reported total third-quarter revenue of $10.6m on Thursday, making for an increase of 5% year-on-year.

Read more
2 Nov 2022 15:43

UK earnings, trading statements calendar - next 7 days

Thursday 3 November 
BT Group PLCHalf Year Results
Gattaca PLCFull Year Results
Glanbia PLCQ3 Results
Helios Towers PLCQ3 Results
Hikma Pharmaceuticals PLCTrading Statement
Howden Joinery Group PLCTrading Statement
J Sainsbury PLCHalf Year Results
Lancashire Holdings LtdTrading Statement
OSB Group PLCTrading Statement
Polymetal International PLCQ3 Results
RS Group PLCHalf Year Results
Rolls-Royce Holdings PLCTrading Statement
Smith & Nephew PLCTrading Statement
TI Fluid Systems PLCTrading Statement
Trainline PLCHalf Year Results
UP Global Sourcing Holdings PLCFull Year Results
WAG Payment Solutions PLCTrading Statement
Wheaton Precious Metals CorpQ3 Results
Woolworths Group LtdQ1 Results
Friday 4 November 
Apax Global Alpha LtdFull Year Results
Monday 7 November 
Great Eastern Energy Corp LtdHalf Year Results
Kingspan Group PLCTrading Statement
Ryanair Holdings PLCHalf Year Results
Tuesday 8 November 
Argentex Group PLCHalf Year Results
Associated British Foods PLCFull Year Results
Aveva Group PLCHalf Year Results
Beximco Pharmaceuticals LtdFull Year Results
Coca-Cola HBC AGTrading Statement
DCC PLCHalf Year Results
Direct Line Insurance Group PLCTrading Statement
Egdon Resources PLCFull Year Results
Hilton Food Group PLCTrading Statement
Marks Electrical Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Persimmon PLCTrading Statement
Warehouse REIT PLCHalf Year Results
YouGov PLCFull Year Results
Zoo Digital Group PLCHalf Year Results
Wednesday 9 November 
Aviva PLCTrading Statement
Biffa PLCHalf Year Results
Conduit Holdings LtdTrading Statement
Dignity PLCTrading Statement
Flutter Entertainment PLCTrading Statement
Gelion PLCFull Year Results
Georgia Capital PLCQ3 Results
Gym Group PLCTrading Statement
JD Wetherspoon PLCTrading Statement
ITV PLCTrading Statement
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Norcros PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Smiths News PLCFull Year Results
Taylor Wimpey PLCTrading Statement
Tracsis PLCFull Year Results
Volex PLCHalf Year Results
Watches of Switzerland Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Sep 2022 21:38

TRADING UPDATES: LoopUp, Surface raise capital; MaxCyte wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Aug 2022 14:31

MaxCyte hikes guidance after solid first half

(Sharecast News) - Cell engineering company MaxCyte reported total first-half revenue of $21.2m on Thursday, up 56% year-on-year, as it increased its guidance for the full year.

Read more
10 Aug 2022 22:01

IN BRIEF: MaxCyte grows revenue but widens loss in second quarter

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says second quarter revenue grew 35% year-on-year to USD9.6 million from USD7.1 million, "driven by strong growth in the cell therapy market; core business revenues grew 45% led by revenue from cell therapy customers which increased 61%, with drug discovery revenues growing by 4%", the firm says. Net loss for the quarter widens to USD8.3 million from US4.4 million. For the first half as a whole, revenue rises 56% year-on-year to USD21.2 million from USD13.6 million, as net loss widens slightly to USD12.3 million from USD11.5 million. Expects core business revenue in full year to grow approximately 30%. Continues to expect SPL Program-related revenue to be around USD4 million for the year. Says is making investments to drive revenue growth, and expand applications for its technology.

Read more
3 Aug 2022 15:57

UK earnings, trading statements calendar - next 7 days

Thursday 4 August 
  
Centamin PLCHalf Year Results
Coca-Cola Europacific Partners PLCHalf Year Results
ConvaTec Group PLCHalf Year Results
Evraz PLCHalf Year Results
Glencore PLCHalf Year Results
Gym Group PLCHalf Year Results
Hikma Pharmaceuticals PLCHalf Year Results
Informa PLCHalf Year Results
Meggitt PLCHalf Year Results
Mondi PLCHalf Year Results
Morgan Sindall Group PLCHalf Year Results
Next PLCTrading Statement
Pantheon International PLCFull Year Results
Premier Miton Global Renewables Trust PLCHalf Year Results
Revolution Beauty Group PLCFull Year Results
Rolls-Royce Holdings PLCHalf Year Results
ScS Group PLCTrading Statement
Secure Trust Bank PLCHalf Year Results
Serco Group PLCHalf Year Results
Spirent Communications PLCHalf Year Results
Tritax Big Box REIT PLCHalf Year Results
TT Electronics PLCHalf Year Results
Friday 5 August 
FBD Holdings PLCHalf Year Results
Hargreaves Lansdown PLCFull Year Results
London Stock Exchange Group PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewables Infrastructure Group LtdHalf Year Results
WPP PLCHalf Year Results
Monday 8 August 
Clarkson PLCHalf Year Results
Diversified Energy Company PLCHalf Year Results
Gran Tierra Energy IncQ2 Results
Griffin Mining LtdHalf Year Results
ITM Power PLCFull Year Results
Kosmos Energy LtdQ2 Results
PageGroup PLCHalf Year Results
RM Infrastructure Income PLCHalf Year Results
Tuesday 9 August 
abrdn PLCHalf Year Results
Bellway PLCTrading Statement
Blue Planet Investment Trust PLCFull Year Results
Burford Capital LtdHalf Year Results
Clarkson PLCHalf Year Results
H&T Group PLCHalf Year Results
InterContinental Hotels Group PLCHalf Year Results
IWG PLCHalf Year Results
Just Group PLCHalf Year Results
Legal & General Group PLCHalf Year Results
Quarto Group IncHalf Year Results
RPS Group PLCHalf Year Results
SIG PLCHalf Year Results
TI Fluid Systems PLCHalf Year Results
Zotefoams PLCHalf Year Results
Wednesday 10 August 
4imprint Group PLCHalf Year Results
Aberdeen New India Investment Trust PLCFull Year Results
Admiral Group PLCHalf Year Results
Arix Bioscience PLCHalf Year Results
Atalaya Mining PLCHalf Year Results
Avast PLCHalf Year Results
Aviva PLCHalf Year Results
Baillie Gifford US Growth Trust PLCFull Year Results
BlackRock Energy & Resources Income Trust PLCHalf Year Results
CLS Holdings PLCHalf Year Results
Computacenter PLCTrading Statement
ContourGlobal PLCHalf Year Results
Deliveroo PLCHalf Year Results
Goodwin PLCFull Year Results
Henderson Smaller Cos Investment Trust PLCFull Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCHalf Year Results
MaxCyte IncQ2 Results
Provident Financial PLCHalf Year Results
Prudential PLCHalf Year Results
Quilter PLCHalf Year Results
S&U PLCTrading Statement
TP ICAP Group PLCHalf Year Results
UK Commercial Property REIT LtdTrading Statement
Videndum PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
12 Jul 2022 14:05

IN BRIEF: MaxCyte enters strategic platform license agreement with LG

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Signs a strategic platform license agreement with Korean chemical company LG Chem Ltd, a subsidiary of LG Corp. Explains that the deal gives LG non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. MaxCyte will receive platform licensing fees and programme related revenue.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.